ZIM Laboratories Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Chandrashekhar Mainde

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3yrs
Gemiddelde ambtstermijn bestuur	7.2yrs

Recente managementupdates

Recent updates

CEO

Chandrashekhar Mainde

less than a year

Tenure

Dr. Chandrashekhar Mainde is CEO & Executive Director of ZIM Laboratories Limited from June 2024. He heads the company’s research and development activity and advises the company on all technical functions...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Anwar Daud	Executive Chairman & MD	15.6yrs	₹17.78m	27.52% ₹ 1.5b
Shyam Patro	Chief Financial Officer	5.6yrs	₹7.75m	geen gegevens
Piyush Nikhade	Company Secretary & Compliance Officer	7.2yrs	₹3.62m	geen gegevens
Niraj Dhadiwal	Director of Business Development & Executive Director	no data	₹9.32m	geen gegevens
Zulfiquar Kamal	Director of Finance & Executive Director	no data	₹11.02m	2.45% ₹ 135.8m
Prakash Sapkal	Head of ODS Business	no data	₹8.68m	0.77% ₹ 42.8m
Chandrashekhar Mainde	CEO & Executive Director	less than a year	geen gegevens	geen gegevens
Pradeep Kataria	Senior Vice President of Operations	no data	geen gegevens	geen gegevens
Vijay Fudke	Senior Vice President of Technical Services	no data	geen gegevens	geen gegevens

3.0yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 541400 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Anwar Daud	Executive Chairman & MD	15.6yrs	₹17.78m	27.52% ₹ 1.5b
Niraj Dhadiwal	Director of Business Development & Executive Director	11yrs	₹9.32m	geen gegevens
Zulfiquar Kamal	Director of Finance & Executive Director	12.1yrs	₹11.02m	2.45% ₹ 135.8m
Prakash Sapkal	Head of ODS Business	11yrs	₹8.68m	0.77% ₹ 42.8m
Chandrashekhar Mainde	CEO & Executive Director	less than a year	geen gegevens	geen gegevens
Gautam Saigal	Non Executive & Non-Independent Director	less than a year	geen gegevens	geen gegevens
Zakir Vali	Chairman Emeritus	no data	₹600.00k	10.36% ₹ 573.4m
Rahul Deshpande	Independent Nominee Director	no data	geen gegevens	geen gegevens
Padmakar Joshi	Independent Director	7.2yrs	₹700.00k	geen gegevens
Kavita Loya	Independent Director	7.2yrs	₹900.00k	0.0074% ₹ 409.1k
Kakasaheb Mahadik	Independent Director	2.6yrs	₹700.00k	0.0049% ₹ 272.9k
Kamlesh Shende	Independent Director	2.6yrs	₹700.00k	geen gegevens

7.2yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 541400 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.2 jaar).

ZIM Laboratories Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

ZIM Laboratories Limited, Annual General Meeting, Jun 27, 2024

ZIM Laboratories Limited, Annual General Meeting, Jul 10, 2023

ZIM Laboratories Limited, Annual General Meeting, Jul 10, 2023

ZIM Laboratories Limited, Annual General Meeting, Sep 19, 2022

High number of new directors

High number of new directors

Recent updates

ZIM Laboratories Limited to Report Q2, 2025 Results on Nov 09, 2024

First quarter 2025 earnings released: EPS: ₹0.18 (vs ₹0.05 in 1Q 2024)

ZIM Laboratories Limited to Report Q1, 2025 Results on Aug 08, 2024

ZIM Laboratories Limited, Annual General Meeting, Jun 27, 2024

Full year 2024 earnings released: EPS: ₹3.54 (vs ₹5.02 in FY 2023)

ZIM Laboratories Limited to Report Q4, 2024 Results on May 13, 2024

Investor sentiment improves as stock rises 16%

Now 34% overvalued after recent price rise

Now 22% overvalued

Now 23% overvalued

Third quarter 2024 earnings released: EPS: ₹0.98 (vs ₹1.35 in 3Q 2023)

ZIM Laboratories Limited to Report Q3, 2024 Results on Jan 29, 2024

ZIM Laboratories Limited to Report Q3, 2024 Results on Jan 29, 2024

Second quarter 2024 earnings released: EPS: ₹0.85 (vs ₹1.12 in 2Q 2023)

ZIM Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023

First quarter 2024 earnings released: EPS: ₹0.05 (vs ₹1.06 in 1Q 2023)

ZIM Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023

Investor sentiment improves as stock rises 23%

Investor sentiment improves as stock rises 17%

ZIM Laboratories Limited (BSE:541400) agreed to acquire 99% stake in Zimtas Pty Ltd for approximately AUD 0.01 million.

New major risk - Share price stability

ZIM Laboratories Limited, Annual General Meeting, Jul 10, 2023

ZIM Laboratories Limited, Annual General Meeting, Jul 10, 2023

Full year 2023 earnings released: EPS: ₹5.01 (vs ₹2.99 in FY 2022)

Investor sentiment improves as stock rises 25%

Third quarter 2023 earnings released: EPS: ₹1.35 (vs ₹0.84 in 3Q 2022)

ZIM Laboratories Limited to Report Q3, 2023 Results on Feb 03, 2023

ZIM Laboratories Limited to Report Q3, 2023 Results on Feb 03, 2023

Second quarter 2023 earnings released: EPS: ₹3.35 (vs ₹2.00 in 2Q 2022)

Investor sentiment improved over the past week

ZIM Laboratories Limited to Report Q4, 2022 Results on Nov 12, 2022

Investor sentiment improved over the past week

ZIM Laboratories Limited, Annual General Meeting, Sep 19, 2022

First quarter 2023 earnings released: EPS: ₹3.17 (vs ₹0.12 in 1Q 2022)

ZIM Laboratories Limited to Report Q1, 2023 Results on Jul 26, 2022

Investor sentiment improved over the past week

High number of new directors

Full year 2022 earnings released: EPS: ₹8.96 (vs ₹4.51 in FY 2021)

Investor sentiment improved over the past week

ZIM Laboratories Limited to Report Q4, 2022 Results on May 21, 2022

High number of new directors

Investor sentiment improved over the past week

ZIM Laboratories Limited Announces Board Changes, Effective April 1, 2022

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹2.00 (vs ₹0.73 in 2Q 2021)

First quarter 2022 earnings released: EPS ₹0.12 (vs ₹2.02 in 1Q 2021)

Director of Administration & Executive Director Riaz Ahmed Kamal has left the company

Zim Laboratories Limited Announces Granting of Marketing Authorization for Rizatriptan Orally Dissolving Film in Portugal

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹4.50 (vs ₹2.04 in FY 2020)

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ₹0.80 (vs ₹0.94 in 3Q 2020)

New 90-day low: ₹79.75

ZIM Laboratories Limited to Report Nine Months, 2021 Results on Feb 11, 2021

New 90-day low: ₹85.00

First half earnings released

Market bids up stock over the past week

First quarter earnings released

New 90-day high - ₹99.60

ZIM Laboratories Limited to Report Q1, 2021 Results on Aug 04, 2020

ZIM Laboratories Limited (BSE:541400) completed the acquisition of an unknown minority stake in ZIM Health Technologies Limited from existing shareholders.

New 90-day high - ₹81.50

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur